Study Summary
Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL
Want to learn more about this trial?
Request More InfoInterventions
MB-106BIOLOGICAL
T-cells derived from autologous leukapheresis that are genetically modified.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| UC Irvine Health - Chao Family Comprehensive Cancer Center | Orange | California | United States |
| Massachusetts General Hospital (MGH) | Boston | Massachusetts | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |
| University of Rochester Medical Center | Rochester | New York | United States |
| Cleveland Clinic | Cleveland | Ohio | United States |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | United States |